11th December 2020

NICE Appraisal Committee recommends that erenumab be used to prevent migraine

Recommends that erenumab be used to prevent both episodic and chronic migraine

There has been good news about erenumab (Aimovig), a medication that is used to treat migraine.

Last year the National Institute for Health and Care Excellence (NICE) decided not to approve it as a treatment for migraine within the NHS in England.

Following an appeal, the NICE Appraisal Committee has issued a Final Appraisal Document recommending that erenumab be used to prevent both episodic and chronic migraine.

This document has been sent to consultees for this appraisal to consider whether they wish to appeal against it. Subject to any appeal, the Final Appraisal Document may be used as the basis for NICE’s guidance on whether erenumab can be used to treat migraine in the NHS in England.

It would be very positive news for migraine patients if it is. It would provide another treatment option to prevent migraine, and one that has proved effective to many people with migraine. Significantly, this would be a treatment option of a medication that was designed specifically to prevent migraine, and one of the new calcitonin gene-related peptide (CGRP) class of drugs.